Novel PRMT5 Inhibitors for Treating Cancer

ADVERTISEMENT RETURN TO ISSUEPREVPatent HighlightNEXTNovel PRMT5 Inhibitors for Treating CancerRam W. Sabnis*Ram W. SabnisSmith, Gambrell & Russell LLP, 1230 Peachtree Street NE, Suite 3100, Atlanta, Georgia 30309, United States*Email: [email protected]More by Ram W. Sabnishttps://orcid.org/0000-0001-7289-0581Cite this: ACS Med. Chem. Lett. 2021, 12, 10, 1537–1538Publication Date (Web):October 4, 2021Publication History Received16 September 2021Published online4 October 2021Published inissue 14 October 2021https://pubs.acs.org/doi/10.1021/acsmedchemlett.1c00512https://doi.org/10.1021/acsmedchemlett.1c00512editorialACS PublicationsCopyright © Published 2021 by American Chemical Society. This publication is available under these Terms of Use. Request reuse permissions This publication is free to access through this site. Learn MoreArticle Views3485Altmetric-Citations7LEARN ABOUT THESE METRICSArticle Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.Citations are the number of other articles citing this article, calculated by Crossref and updated daily. Find more information about Crossref citation counts.The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on the Altmetric Attention Score and how the score is calculated. Share Add toView InAdd Full Text with ReferenceAdd Description ExportRISCitationCitation and abstractCitation and referencesMore Options Share onFacebookTwitterWechatLinked InRedditEmail PDF (758 KB) Get e-AlertscloseSUBJECTS:Alkyls,Cancer,Cytosine,Genetics,Inhibitors Get e-Alerts